Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial-Reference-Cited by-全球学者库

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Published:2022-08 Issue:8 Volume:10 Page:739-748
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Li Jing-Xin,Wu Shi-Po,Guo Xi-Ling,Tang Rong,Huang Bao-Ying,Chen Xiao-Qin,Chen Yin,Hou Li-Hua,Liu Jing-Xian,Zhong Jin,Pan Hong-Xing,Shi Feng-Juan,Xu Xiao-Yu,Li Zhuo-Pei,Zhang Xiao-Yin,Cui Lun-Biao,Tan Wen-Jie,Chen Wei,Zhu Feng-Cai,Li Jing-Xin,Wu Shi-Po,Guo Xi-Ling,Tang Rong,Huang Bao-Ying,Chen Xiao-Qin,Chen Yin,Hou Li-Hua,Liu Jing-Xian,Zhong Jin,Pan Hong-Xing,Shi Feng-Juan,Xu Xiao-Yu,Li Zhuo-Pei,Zhang Xiao-Yin,Cui Lun-Biao,Tan Wen-Jie,Chen Wei,Zhu Feng-Cai,Huang Hai-Tao,Gou Jin-Bo,Si Wei-Xue,Wang Xue,Zhao Xiao-Long,Zhu Tao

Funder

Jiangsu Provincial Key Research and Development Program

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. Duration of protection against mild and severe disease by Covid-19 vaccines;Andrews;N Engl J Med,2022

2. Emergence of a novel SARS-CoV-2 variant in southern California;Zhang;JAMA,2021

3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial;Munro;Lancet,2021

4. Protection of BNT162b2 vaccine booster against Covid-19 in Israel;Bar-On;N Engl J Med,2021

5. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen;Keskin;J Med Virol,2022

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary inhalation for disease treatment: Basic research and clinical translations;Materials Today Bio;2024-04

2. The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2;ACS Omega;2024-01-26

3. Fibronectin mediates activin A-promoted human trophoblast migration and acquisition of endothelial-like phenotype;Cell Communication and Signaling;2024-01-23

4. Enhanced immunity against SARS-CoV-2 in returning Chinese individuals;Human Vaccines & Immunotherapeutics;2024-01-08

5. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos);eClinicalMedicine;2024-01